Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

NCNA


Top 10 Correlated ETFs

NCNA


Top 10 Correlated Stocks

NCNA


In the News

01:33 03 Oct 2022 NCNA

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11:17 03 Oct 2022 NCNA

Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

03:40 03 Oct 2022 NCNA

NuCana: An Intriguing 'Sum Of The Parts' Story

Today, we revisit a small oncology development outfit called NuCana plc for the first time in a year-and-a-half. NuCana plc has early/mid-stage assets in development as well as the chance of a significant litigation settlement at some point.

06:00 03 Oct 2022 NCNA

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

NuCana trades at a bit more than half its cash position as a result of a March 2022 sell-off, caused by the trial discontinuation of the furthest-advanced drug candidate. The company's current drug candidates, NUC-3373 and NUC-7738, show remarkable results across different solid tumors, either substantially improving chemotherapy or creating novel treatment.

01:52 03 Oct 2022 NCNA

Why NuCana Shares Are Rising Today?

Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European Patent 2955190 through their sales of Sovaldi, Harvoni, Vosevi and.

04:01 03 Oct 2022 NCNA

NuCana to Participate in Two Upcoming Investor Conferences

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming virtual investor conferences.

10:49 03 Oct 2022 NCNA

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

11:09 03 Oct 2022 NCNA

NuCana: Preparing For A Critical 2022

NuCana: Preparing For A Critical 2022

11:39 03 Oct 2022 NCNA

NCNA Stock: Why It Substantially Increased Today

The stock price of NuCana PLC (NASDAQ: NCNA) increased by over 20% during intraday trading today. This is why it happened.

09:22 03 Oct 2022 NCNA

Why Are NuCana Shares Moving Higher On Wednesday?

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced the enrollment of 418 evaluable patients in the Phase 3 study, which is expected to enable the first interim analysis in 1H of 2022.

Financial details

Company Rating
Neutral
Market Cap
54.54M
Income
-33.98M
Revenue
0
Book val./share
1.07
Cash/share
0.89
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
16 Nov 2022
P/E
-1.17
Forward P/E
-
PEG
0.36
P/S
-
P/B
0.71
P/C
1.17
P/FCF
-1.35
Quick Ratio
5.46
Current Ratio
5.83
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
-3.7%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-56.25%
-
-
-
-
SMA20
-27.45%
SMA50
-22.38%
SMA100
63.24%
Inst Own
31.11%
Inst Trans
-2.46%
ROA
-51%
ROE
-53%
ROC
-0.74%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
52.2M
Shs Float
32.2M
-
-
-
-
Target Price
-
52W Range
0.517-3.32
52W High
-
52W Low
-
RSI
31.87
Rel Volume
0.3
Avg Volume
314.62K
Volume
94.98K
Perf Week
-25.36%
Perf Month
-32.58%
Perf Quarter
10.7%
Perf Half Y
2.45%
-
-
-
-
Beta
1.27634
-
-
Volatility
0.05%, 0.22%
Prev Close
2.45%
Price
1.045
Change
11.17%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-0.89-0.43-0.66-0.81-0.78
Operating cash flow per share
-0.34-0.38-0.73-0.57-0.46
Free cash flow per share
-0.38-0.43-0.77-0.61-0.48
Cash per share
3.342.391.62.311.16
Book value per share
3.62.541.962.621.26
Tangible book value per share
3.532.441.842.491.21
Share holders equity per share
3.62.541.962.621.26
Interest debt per share
000.020.020.01
Market cap
469.02M317.43M130.26M159.83M99.15M
Enterprise value
382.31M240.46M79.1M73.12M39.26M
P/E ratio
-20.32-22.94-6.08-5.21-2.45
Price to sales ratio
00000
POCF ratio
-53.86-25.97-5.47-7.39-4.16
PFCF ratio
-47.84-22.92-5.19-6.87-3.98
P/B Ratio
5.023.892.051.611.51
PTB ratio
5.023.892.051.611.51
EV to sales
00000
Enterprise value over EBITDA
-17.23-9.79-3.3-2.56-0.94
EV to operating cash flow
-43.9-19.67-3.32-3.38-1.65
EV to free cash flow
-39-17.36-3.15-3.14-1.58
Earnings yield
-0.05-0.04-0.16-0.19-0.41
Free cash flow yield
-0.02-0.04-0.19-0.15-0.25
Debt to equity
000.0100
Debt to assets
0.030.060.10.080.15
Net debt to EBITDA
3.913.132.143.031.43
Current ratio
32.2215.0210.5412.496.11
Interest coverage
0000-465.1
Income quality
0.380.881.110.70.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.020.040.060.040.03
Capex to operating cash flow
0.130.130.050.080.04
Capex to revenue
00000
Capex to depreciation
-5.64-4.38-1.76-1.83-1.13
Stock based compensation to revenue
00000
Graham number
8.494.955.396.914.7
ROIC
-0.27-0.23-0.42-0.37-0.73
Return on tangible assets
-0.24-0.16-0.32-0.3-0.54
Graham Net
3.372.331.62.291.05
Working capital
91.06M78.02M58.97M93.66M59.9M
Tangible asset value
91.48M78.47M59.56M94.48M63.14M
Net current asset value
91.04M78M58.41M93.24M59.69M
Invested capital
000.010.010.01
Average receivables
7.71M7.73M9.86M10.65M9.42M
Average payables
1.69M2.36M2.33M2.26M2.04M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.25-0.17-0.34-0.31-0.62
Capex per share
-0.04-0.05-0.04-0.04-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00000
Net income per share
-0.17-0.15-0.17-0.16-0.07
Operating cash flow per share
-0.09-0.02-0.13-0.17-0.17
Free cash flow per share
-0.1-0.02-0.13-0.17-0.18
Cash per share
1.411.360.751.010.89
Book value per share
1.611.480.811.131.07
Tangible book value per share
1.521.390.781.131.07
Share holders equity per share
1.611.480.811.131.07
Interest debt per share
0.010.0100.010.01
Market cap
105.48M98.25M139.88M38.06M27.62M
Enterprise value
32.56M27.66M79.99M-14.21M-18.67M
P/E ratio
-2.9-3.05-2.56-1.13-1.77
Price to sales ratio
00000
POCF ratio
-21.72-122.05-13.87-4.41-3.05
PFCF ratio
-20.8-95.48-13.23-4.33-3.01
P/B Ratio
1.251.272.130.650.49
PTB ratio
1.251.272.130.650.49
EV to sales
00000
Enterprise value over EBITDA
-3.17-2.25-8.51.131.68
EV to operating cash flow
-6.7-34.36-7.931.652.06
EV to free cash flow
-6.42-26.88-7.571.622.04
Earnings yield
-0.09-0.08-0.1-0.22-0.14
Free cash flow yield
-0.05-0.01-0.08-0.23-0.33
Debt to equity
00000
Debt to assets
0.090.140.150.180.16
Net debt to EBITDA
7.15.746.374.174.17
Current ratio
116.726.115.245.83
Interest coverage
00-715.32-337.65-39.53
Income quality
0.530.10.741.032.32
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.050.050.0300
Capex to operating cash flow
0.040.280.050.020.01
Capex to revenue
00000
Capex to depreciation
-0.96-0.98-1.8-0.84-0.44
Stock based compensation to revenue
00000
Graham number
2.522.271.762.021.34
ROIC
-0.13-0.13-0.24-0.18-0.09
Return on tangible assets
-0.1-0.09-0.18-0.12-0.06
Graham Net
1.381.20.680.90.84
Working capital
78.58M69.21M59.9M53.05M50.43M
Tangible asset value
79.38M72.55M63.14M00
Net current asset value
78.3M68.97M59.69M52.86M50.27M
Invested capital
0.010.010.010.010
Average receivables
9.02M7.18M8.71M9.22M9.81M
Average payables
2.2M3.3M2.26M2.7M2.42M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.1-0.21-0.14-0.07
Capex per share
00-0.0100

Frequently Asked Questions

What is NuCana plc stock symbol ?

NuCana plc is a GB stock and trading under the symbol NCNA

What is NuCana plc stock quote today ?

NuCana plc stock price is $1.045 today.

Is NuCana plc stock public?

Yes, NuCana plc is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap